Latest News

Wednesday, March 21, 2018 | Neuromuscular, Research and Publications

Mutations in the Gene for Muscle Protein Kinesin A Cause of Amyotrophic Lateral Sclerosis

As published in today’s issue of the journal Neuron, researchers have identified specific mutations in the kinesin family gene, KIF5A, that cause amyotrophic lateral sclerosis (ALS) (Neuron. 201…

Read the full story

Tuesday, March 20, 2018 | Clinical Trials, Dementia & Cognitive Disorders

Global Alzheimer's Platform Foundation Partners with Lyft to Provide Free Transportation to Research Sites for Clinical Trial Participants

In partnership with Lyft (San Francisco, CA), the Global Alzheimer's Platform Foundation (GAP) (Washington, DC) is beginning a pilot program to provide free transportation to and from research sit…

Read the full story

Friday, March 16, 2018 | Dementia & Cognitive Disorders, Stroke & Cerebrovascular

Arterial Stiffness is Associated with Amyloid-Beta Deposition and Lower Brain Volume in Alzheimer Disease-Susceptible Regions

Results from the atherosclerosis risk in communities (ARIC)-neurocognitive study published today (Neurology. 2018;published online ahead of print March 16, 2018) show an association between arterial s…

Read the full story

Friday, March 16, 2018 | Multiple Sclerosis & Immune Disorders, Neuromuscular

Subcutaneous Immune Globulin Approved for Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Already approved in 51 countries for some immune deficiencies, subcutaneous immune globulin (IG) (Hizentra; King of Prussia, PA) has now been approved by the Food and Drug Administration (FDA) for tre…

Read the full story

Thursday, March 15, 2018 | Neuromuscular

Positive Results for Phase 2 Proof-of-Concept Study for Congenital and Childhood Onset Myotonic Dystrophy Type 1

The results of a phase 2 proof-of concept study of AMO-02, an investigational therapy for childhood-onset myotonic dystrophy type 1 were presented at the Muscular Dystrophy Association Meeting this we…

Read the full story

Wednesday, March 14, 2018 | Clinical Trials, Epilepsy & Seizure Disorders

Results From Cannabidiol Dose-Ranging Safety Trial for Treating Patients With Dravet Syndrome

Previous randomized controlled trials have suggested that orally administered cannabidiol (CBD) is effective as an add-on to existing antiepileptic drugs (AEDs) for the treatment of convulsive seizure…

Read the full story

Tuesday, March 13, 2018 | Neuromuscular

Phase I/IIa Clinical Trial of Stem Cell Therapy for Amyotrophic Lateral Sclerosis Begins in Israel

Approval has been granted by the Israel Ministry of Health’s Supreme Committee for Kadimastem (NessZiona, Israel) to immediately begin a phase I/IIa clinical trial of their stem cell therapy to …

Read the full story

Monday, March 12, 2018 | Movement Disorders

Phase 1 Trial Initiated for Product Candidate CAD-1883, Hoped to Provide Treatment for Spinocerebellar Ataxia and Essential Tremor

Novel therapeutics developer, Cadent Therapeutics (Cambridge, Massachusetts) has initiated a phase 1 clinical trial for product candidate CAD-1883, which is an allosteric modulator of the small conduc…

Read the full story

Wednesday, March 07, 2018 | Headache & Pain, Imaging & Testing

Biomarkers Available to Speed Diagnosis of Fibromyalgia

Iquity (Nashville, Tennessee) has announced the release of IsolateFibromyalgia, an RNA analysis of blood samples, for the fast and accurate detection of fibromyalgia syndrome. IsolateFibromyalgia s…

Read the full story

Tuesday, March 06, 2018 | Clinical Trials, Headache & Pain

First Patient Enrolled in Phase 3 Clinical Trial of Rimegepant for Acute Migraine Treatment

Biohaven Pharmaceutical (New Haven, CT) announced today the first patient enrollment in their phase 3 clinical trial of rimegepant (Zydis) for the acute treatment of migraine.  Zydis is an orally…

Read the full story

Monday, March 05, 2018 | Business of Medicine, Healthcare and Regulation, Healthcare Trends, Practice Management

American Academy of Neurology Praised for New Neutral Stance on Lawful Physician-Hastened Death

The American Academy of Neurology (AAN) received praise for a new position statement published in late February 2018 that rescinds the AAN 1998 position against medically-assisted suicide, or law…

Read the full story

Friday, March 02, 2018 | Multiple Sclerosis & Immune Disorders

Consuming Fish and/or Omega-3 Fatty Acids 1-3 Times Per Week May Decrease Risk of Multiple Sclerosis

A preliminary study funded by the National Institute of Neurologic Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), shows that there is a correlation between consumptio…

Read the full story

Thursday, March 01, 2018 | Business of Medicine, General Medicine, Headache & Pain, Movement Disorders, Neuromuscular

Biosimilar Being Developed for Botox

In a transatlantic collaboration, Mylan N.V. (Pittsburgh, Pennsylvania) and Revance Therapeutics, Inc. (Hertsfordshire, England) have reached an agreement to collaborate on the development and commerc…

Read the full story

Thursday, March 01, 2018 | Multiple Sclerosis & Immune Disorders

Multiple Sclerosis Association of America Kicks Off Understanding Multiple Sclerosis Progression Campaign for Multiple Sclerosis Awareness Month

For multiple sclerosis (MS) Awareness Month, the Multiple Sclerosis Association of America (MSAA) focuses on their campaign on Understanding MS Progression. Specific topics address…

Read the full story

Wednesday, February 28, 2018 | Concussion & Brain Injury, New Tag

Boston University Ryan Center for Sports Medicine and Seqster Collaborate on New Proof-of-Concept Study for Traumatic Brain Injury Biomarkers

The Boston University Ryan Center for Sports Medicine and Related Services and Seqster (San Diego, California) plan to partner in the Ryan Center’s proof of concept study for identifying potenti…

Read the full story
Load More